Chewy vs. Coupang: Which E-Commerce Stock Is a Better Buy in 2026?

Coupang is presented as the preferred long-term e-commerce investment despite cybersecurity, legal and regulatory overhangs, supported by FY2025 revenue growth of 14.1% to $34.5B and expansion across logistics, fintech and Taiwan. Chewy generated FY2025 revenue of $12.6B, up 6.2%, with a higher 1.8% net margin versus Coupang's 0.6%, and trades at a substantially lower 14.2x forward P/E versus 69.9x. The article argues Coupang's larger growth runway outweighs near-term fallout from its November 2025 customer data incident, while Chewy offers steadier Autoship-led pet-care exposure.

Analysis

The apparent valuation discount in CHWY is not automatically cheap: its cash conversion is materially flattered by equity compensation, while sub-2% net margins leave little room for freight, pet-food deflation, or promotional pressure from AMZN, WMT, and Petco. The more important upside variable is whether veterinary software and pharmacy attach rates turn the customer relationship into a higher-margin ecosystem; that would warrant a multiple re-rating over 6-18 months, but it needs evidence of service revenue growth and gross-margin expansion rather than another quarter of modest retail growth.

CPNG's premium embeds a difficult transition from a domestic logistics leader to a multi-vertical platform without sustained margin dilution. Taiwan, Farfetch, Eats, and fintech can create cross-sell and delivery-density benefits, but they also consume capital before they contribute earnings; a strong revenue print alone is insufficient. For the next 1-3 months, regulatory, litigation, and remediation disclosures tied to the data incident are more likely to set the stock than core-commerce KPIs, while KRW weakness would further dilute reported USD growth.

Contrarian view: the market is likely underpricing CHWY's potential operating leverage if pet-health services monetize its existing customer base, and overpricing CPNG's ability to fund international expansion while preserving a very high earnings multiple. The cleaner expression is relative rather than outright: CHWY has lower growth but a nearer pathway to demonstrable margin improvement; CPNG has the stronger long-term platform but substantially greater execution and event risk.

Key Decisions for Investors

• Initiate a 3-6 month pair trade: long CHWY / short CPNG, sized beta-neutral. Target a 15-20% relative return if CHWY demonstrates gross-margin expansion or veterinary/pharmacy monetization while CPNG faces incident-related charges or investment-margin pressure; exit if CHWY active-customer trends deteriorate and adjusted EBITDA margins fail to improve, or if CPNG shows sustained margin expansion despite expansion spend.
• Do not underwrite CHWY on reported free cash flow alone. Add only after the next earnings release confirms that stock-based-compensation dilution is moderating and that service/pharmacy revenue is growing faster than core consumables; absent those datapoints, the low earnings multiple may be a value trap rather than a catalyst.
• For CPNG holders, reduce tactical exposure ahead of material regulatory or litigation updates and re-enter only if quantified breach costs are below consensus and product-commerce contribution margin remains resilient. A Taiwan growth acceleration without worsening consolidated operating margin would falsify the bearish relative thesis.
• Monitor AMZN and WMT pricing and delivery investments as a read-through for CHWY: renewed broad-based online price competition would pressure CHWY's consumables margin first, whereas stable pricing combined with higher Autoship retention would support a 6-18 month long thesis.